Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Multimodal Pain Package vs. Regular Formulation for Pain Management in Ambulatory Spinal Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 100
- Registration Number
- NCT05965492
- Locations
- 🇺🇸
university of Miami, Miami, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH
- Conditions
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- shifeng Lou
- Target Recruit Count
- 160
- Registration Number
- NCT05936086
- Locations
- 🇨🇳
The Second affiliated Hosptial of Chongqing medical University, Chongqing, China
Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT05932524
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, China
🇨🇳Beijing Friendship Hospital, Beijing, China
🇨🇳Beijing Hospital, Beijing, China
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05922501
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
PANDORA: Paravertebral AdjuNctive DexamethasOne Palmitate Reducing Chronic Pain After Caridiac Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 902
- Registration Number
- NCT05920967
- Locations
- 🇨🇳
Xijing Hospital, Xi'an, China
Comparison Between Bupivacaine and Bupivacaine- Dexamethasone QLB for Postoperative Analgesia
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 60
- Registration Number
- NCT05918796
- Locations
- 🇪🇬
Ain Shams University Hospital, Cairo, EL Abassia, Egypt
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT05911321
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Dong-A University Hospital
- Target Recruit Count
- 49
- Registration Number
- NCT05909826
SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2023-08-14
- Target Recruit Count
- 35
- Registration Number
- NCT05900882
- Locations
- 🇨🇳
Nanjing First People's Hospital, Nanjing, Jiangsu, China
🇨🇳The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳Taizhou People's Hospital, Taizhou, Jiangsu, China
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Carl Ola Landgren, MD, PhD
- Target Recruit Count
- 30
- Registration Number
- NCT05896228
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.